Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG3667 DDI study with Midazolam
NCT04736927Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Jan 2021
- Primary completion
- Feb 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cadefrecitinib in psoriasis, dermatomyositis (DM) and systemic lupus erythematosus (SLE), sponsored by Galapagos NV. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity and Maximum Observed Plasma Concentration. Started Jan 2021; status: completed.
02
Drugs
cadefrecitinib
03
Conditions
psoriasisdermatomyositis (DM)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04736927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04736927.